TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04398927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Systemic Chemotherapy (Oxaliplatin，5-fluorouracil and Irinotecan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab
Study: NCT03304158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCHV visit
Description: FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
Study: NCT04563143

Intervention type: OTHER
Group type: OTHER
Intervention: Novel DBS Stimulation
Description: Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
Study: NCT00217607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02804113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera Peripheral Stent System
Study: NCT03013803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutricomp Drink Plus Fibre
Study: NCT01209689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02393378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Namilumab
Description: Namilumab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic Acid Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid Tablet
Study: NCT04598802

Intervention type: DEVICE
Intervention: covered stent
Description: atherosclerotic aorto-iliac aneurysm
Study: NCT03714672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/Diclofenac 50/50
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/Diclofenac 25/25
Description: Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 50
Description: Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 50
Description: Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
Study: NCT04179669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered by subcutaneous injection
Study: NCT04349397

Intervention type: BEHAVIORAL
Intervention: Medication Tracking Form
Description: Parents will complete medication tracking form for 5 days after child's surgery. They will track medications administered, pain scores, nausea and vomiting
Study: NCT04377893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye gaze AT intervention
Description: The eye-gaze AT intervention includes eye-gaze AT and service delivery to support the participants using this technology in daily life. The Tobii PCEye Mini (Tobii, Danderyd, Sweden) and specialized software are applied with adaptation to meet each child's individual needs.~To ensure the consistency of service delivery, two-day courses are conducted before the intervention. The participant's teachers or parents are invited as the main interventionist to facilitate the child's usage of eye-gaze AT in daily life under team support. The service delivery involves parents in joint goal-setting, planning, and jointly review the progress of the usage of eye-gaze AT as a family-centered practice. Individual meetings and individual supports are provided during intervention periods. The collaborative team will perform biweekly follow-up contacts during intervention periods.~The researcher will conduct the fidelity checklist every month to determine the extent of treatment integrity.
Study: NCT00741182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-34)
Description: Injection of 20 micrograms per day in eight weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-34)
Description: Injection of 20 micrograms per day in eight weeks
Study: NCT01628666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incremental
Description: Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Cefazolin preoperative
Study: NCT02268357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Oral propranolol capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Oral propranolol capsules
Study: NCT03807856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Mesylate
Description: Dabigatran 150mg BID for 3 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Daily vital signs, lab work and one outpatient clinic visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Daily vital signs, lab work and one outpatient clinic visit
Study: NCT04748198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorneal ring segment implantation
Description: Surgical procedure for keratoconus treatment. A tunnel is created in the corneal stroma with femtosecond laser and ring segments are implanted in the corneal stroma
Study: NCT03077412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study: NCT00055757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03478098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest
Description: Meal with low glycaemic index (GI) is consumed over 20 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest
Description: Meal with low glycaemic index (GI) is consumed over 20 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest and subsequent exercise
Description: Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI mealtest and subsequent exercise
Description: Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest
Description: Meal with high glycaemic index (GI) is consumed over 20 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest
Description: Meal with high glycaemic index (GI) is consumed over 20 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest and subsequent exercise
Description: Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI mealtest and subsequent exercise
Description: Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
Study: NCT02549872

Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.

Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on the retrospective analysis of linked electronic health records.
Study: NCT03208647

Intervention type: OTHER
Intervention: AA or not
Description: to study their risk factors
Study: NCT03317184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periumbilical incision
Description: A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Description: Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
Study: NCT02911584

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic procedure
Study: NCT04381754

Intervention type: DEVICE
Intervention: Passeo-18 Lux
Description: Patients with significant inflow or outflow stenosis between the anastomosis to the axillary-subclavian vein junction, as defined by the insertion of the cephalic vein, who had undergone fistuloplasty with Passeo-18 Lux
Study: NCT00874094

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin matrix
Description: 0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
Study: NCT01856959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate & albuterol
Description: 0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: 0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
Study: NCT03976219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECAPS Closed Loop SCS
Description: The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
Study: NCT01110902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO178C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine (AGO178C)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04731545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: Minimally traumatic tooth extraction, immediate implant placement and hard tissue grafting. loading after 3 months.
Study: NCT00489593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
Study: NCT00722943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Massage Therapy
Description: Tactile stimulation and massage will be done by a licensed therapist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: The infant will not be touched by the therapist.
Study: NCT02085161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to tiotropium + olodaterol
Description: comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol
Description: tiotropium 5 mcg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium +olodaterol
Description: olodaterol 5 mcg once daily fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: tiotropium 5 mcg once daily fixed dose combination
Study: NCT01394003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: administered orally
Study: NCT03036202

Intervention type: DRUG
Intervention: Epinephrine
Description: This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
Study: NCT00584636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulmicort respules
Description: pulmicort respules 0.5 mg twice a day for 28 days versus placebo
Study: NCT05510232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will watch a non-VR video via an iPad
Description: The iPad is a tablet computer first offered by Apple in 2010.The device resembles a much larger version of Apple's iPhone or its iPod Touch, and is about the same size as a magazine.The iPad uses the same operating system as the Apple iPhone, and uses very similar hardware. iPad will be used to deliver non VR video to patients.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will have headset on and will watch a non-VR video
Description: Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver non VR video to patients. Headset will be administered before intervention and removed at the completion of the intervention unless patient requests otherwise. Patients visual field will not change with head motion and will remain static throughout cast removal or pin/suture removal.~A standardized age appropriate video will be used for patients between ages 4-9 and a different standardized age appropriate video for patients ages 10-14. The selected videos will be the same for both the cast and suture/pin removal groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A treatment group that will be immersed in the VR game (Bear Blast) via the headset.
Description: VR using the Samsung Gear Oculus headset fitted with a Samsung Galaxy S7 phone will deliver VR images and sound. Patients will watch a 15-minute VR experience called Bear Blast. Bear Blast is an immersive, 360-degree, game experience that takes place in a fantasy world where the user attempts to shoot balls at a wide range of moving objects by gently maneuvering his or her head toward the targets. Bear Blast is a nonviolent and noncompetitive game that incorporates motivational music and features positively reinforcing sounds, animation, and direct messages to patients. Bear Blast will be used as the standardized game for all patients in the VR group of both study arms. The VR reality Samsung Oculus headset can be controlled entirely via head motion and does not involve the use of patients extremities. iPad will be set up and held for patients in the iPad group.
Study: NCT01647217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terpinen-4-ol
Description: Lid scrub once or twice per day for one month.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lid scrub once or twice per day for one month
Study: NCT02949284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Receptor Antagonist ARN-509
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Receptor Antagonist ARN-509
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-releasing Hormone Analog
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study: NCT03995602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dragon fruit juice drink
Description: Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dragon fruit juice drink
Description: Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drink with macro- and micro-nutrient matched against the intervention drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drink with macro- and micro-nutrient matched against the intervention drink.
Study: NCT03570710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid
Description: 1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tranexamic acid
Description: 2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
Study: NCT02532803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Pelvic MRI scan assessment
Description: A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
Study: NCT02850913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: * 115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~* Treatment will be initiated in hospital but will be continued at home.~* Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~* Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Placebo (matching capsules containing no active ingredients)
Study: NCT02698553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl XL tablet 150mg
Description: The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion HCl XL tablet 300mg
Description: The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
Study: NCT00997776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive resistance exercise
Description: lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
Study: NCT02298010

Intervention type: DRUG
Intervention: Capecitabine, oxaliplatin
Study: NCT03349034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivicaine
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Saline Infusion
Description: Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
Study: NCT01065987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg